Trials / Terminated
TerminatedNCT02868892
A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Western Regional Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix will receive Pemetrexed.
Detailed description
Patients will receive Pemetrexed 500 mg/m2 every three week. On initiation of pemetrexed, on day one of first chemotherapy cycle, patients will begin taking folic acid at a dose of 350 to 600 mcg daily as well as receive an intramuscular injection of 1000 mcg of vitamin B12, with subsequent vitamin B12 injections given every 9 weeks while on study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemetrexed | Pemetrexed 500 mg/m2 |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-01
- First posted
- 2016-08-16
- Last updated
- 2018-11-02
- Results posted
- 2018-11-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02868892. Inclusion in this directory is not an endorsement.